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The five Ig classes have distinct biological roles. The IgG subclasses also show
marked differences in their ability to mediate a variety of effector functions. A
detailed comparison of the properties of the human Ig classes and subclasses is
not only of interest for relating the functions of antibodies to their structures
but is also of great importance for the implementation of therapy based upon
immunological intervention . Indeed, this second aspect has become particularly
significant as the development of techniques for the production of chimeric
antibodies (1-3) should ensure that immunological intervention is now likely to
make use of mAbs that have human effector functions; several cell lines have
already been established that secrete chimeric antibodies directed against human
cancer cells (4-6).
Much of our knowledge of the properties of human Igs has been obtained
from the study of myeloma proteins (reviewed in references 7-9). However,
generally myeloma proteins do not bind identified antigens and, moreover,
different myeloma proteins differ not only in their heavy chain class/subclass but
also in their light chains and variable regions. As the initiation of antibody
effector activity is usually a consequence of antigen binding and is indeed
influenced by the quality ofthat binding, previous studies on myeloma proteins,
although valuable, may not provide a sufficient picture of antibody effector
function for therapeutic purposes. To carry out a detailed and controlled
comparison of the effector functions of the different human C regions, we have
established a panel of cell lines that secrete a matched set of human chimeric
antibodies. These antibodies are directed against the hapten 4-hydroxy-3-nitro-
phenacetyl (NP).' This specificity for a known hapten has allowed us to compare
the effector functions of the IgG subclasses not only when interacting with
soluble antigen but also when interacting with cell-bound antigen. This has
enabled us to determine the efficacy with which different subclasses lyse their
This work wassupportedby grants from the Medical Research Counciland Wellcome Biotechnology.
' Abbreviations used in this paper.
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ADCC, antibody-dependent cell-mediated cytotoxicity, NP,
nitrophenacetyl; NIP, 5-iodo-4-hydroxy-3-nitrophenyl .
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target cells by means of both cell-mediated and complement-dependent mecha-
nisms .
Materials and Methods
Plasmids .
￿
Plasmid pSV-VNP (Fig . 1) contains a single Bam HI site for the insertion of
restriction fragments containing C exons; this plasmid, as well as pSV-VNPHe, has been
previously described (3) . Derivatives ofpSV-VNP with Xba I or Hind III sites in place of
the Bam HI site were createdby insertingoctameric linkers into the Bam HI site that had
been blunted using Escherichia coli DNA polymerase I Klenow fragment . Construction of
the Hind III vector required prior destruction of two other Hind III sites in pSV-VNP by
Klenow treatment . The origin and manipulation of the DNA inserts specifying the
different C genes is described in the legend to Fig . 1 .
Cell Lines' and Transfection. J558L plasmacytoma cells (10) were obtained from Dr .
S . L. Morrison (Dept . of Microbiology, College of Physicians and Surgeons, Columbia
Univ ., New York) and were grown in DME containing 10% FCS. Transfection was
performed by spheroplast fusion (11) in the case of the IgG2-, IgG4-, and IgE-secreting
cell lines, and by electroporation for the other constructs . For electroporation (12), 2 x
10' cells that had been washed and resuspended in 0 .2 ml cold PBS were mixed with
linearized plasmid DNA (15 gg in 20 Al H2O) and placed in a 1 cm x 0.4 cm x 4.5 cm
plastic microcuvette that had been equipped with aluminum electrodes . The sample was
given 15 2-kV pulses at 1-s intervals from an Apelex power supply, left on ice for 30 min,
and then resuspended in 50 ml DME/10% FCS/gentamycin before transferring to 24-
well plates. Selective medium containing mycophenolic acid was applied 24 h later (11) .
Anti-NP antibody in the culture medium was assayed by RIA (13) and cells were cloned
by limiting dilution .
Protein Purification andAnalysis.
￿
Forantibody purification, cells were allowedto grow
to saturation in 2 liters ofDME/10% FCS.Theculturemedium was filtered,supplemented
to 0.05% in NaN3, and passed over a 5-iodo-4-hydroxy-3-nitrophenacetyl (NIP)-caproate
Sepharose affinity column . This column was prepared according to a procedure provided
byM. Cramer (University of Cologne, Cologne, Federal Republic of Germany) . 80 ml of
Sepharose CL-4B (Pharmacia Fine Chemicals, Uppsala, Sweden) that had been washed
and resuspended in an equal volume of ice-cold 2 M Na2CO3 , was activated by mixing
with 4 ml of 0.5 g/ml CNBr in acetonitrile . After extensive washing, the activated
Sepharose was mixed with 40 ml of bis(3-aminopropyl)amine that had been brought to
pH 10 by the slow addition of 12M HCl atVC. C. After gentle mixing overnight at VC, C,
the derivatized Sepharose was washed in H2O, resuspended in cold 3% NaHC03 and
mixed with 60 mg of NIP-caproate-O-succinimide (Cambridge Research Biochemicals,
Harston, Cambridge) that had been dissolved in 1 ml dioxane. After mixing overnight at
4°C, the NIPcap-Sepharose was washed with 0.1 M glycine/HCI, pH 3, followed by PBS
and then stored in PBS/0.05% NaN3 . After sampleshad been passed throughthe column
and extensive washing, antibody was eluted from the sorbent with 0.5 mM NIP-caproate
or NP-caproate in PBS and dialyzed extensively. Antibody samples were centrifuged
extensively to remove aggregates .
Protein samples were analyzed on SDS/PAGE gels (14) . Samples were also purified on
NIP-caproate Sepharose from cells labeled with [ 'Cl-L-lysine in the presence or absence
of 10 pg/ml tunicamycin as previously described (15) .
Serological Assays.
￿
Serologic analysis wasperformed in an ELISAassay as follows : wells
of flat-bottomed microtiter plates were coated overnight at 4°C with 100 ill purified anti-
NP antibody diluted to 1 jig/ml in 0.2 M NaHC03 , pH 9.6, or with purified human
paraproteins of serologically defined class, subclass, and allotype . After washing with
PBS/0.05% Tween 20 (PBS/Tween), 100 pl of a 1:100 dilution of mAb ascitic fluid in
2 The cell lines will be deposited in the European Centre of Animal Cell Cultures, PHLS Centre
for Applied Microbiology and Research, Porton Down, Salisbury, Wilts.SP4 OJG, United Kingdom,
where they may be obtained by scientists affilitated with nonprofit research in pursuance of an
academic research program .BROGGEMANN ET AL .
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PBS/Tween was added to each well and incubated at 37°C for 2 h . After extensive
washing with PBS/Tween, 100 A,1 of a 1 :4,000 dilution in PBS/Tween ofpolyclonal sheep
anti-mouse Ig antibody conjugated to horseradish peroxidase (BDS Biologicals Ltd .,
Birmingham, United Kingdom) was added and incubated for a further 2 h at 37'C before
repeated washing in PBS/Tween . Bound sheep antibody was revealed by addition of the
substrate (2 .2 mM o-phenylene diamine) . The reaction was quenched after 15 min by the
addition of 50 g.l 12.5% H2SO4 and the OD295 was measured using a Titertec Miniscan
(Flow Laboratories, Irvine, Scotland) . Positive reactions were scored where the OD295 was
0.5 OD units above control values .
Protein A Binding .
￿
Purified antibodies (100 tig/ml in PBS) were coated onto the wells
ofmicrotiter plates (Cooke ; Dynatech Laboratories, Inc ., Alexandria, VA) before blocking
with PBS/3% BSA . The wells were then incubated with ["'I]protein A (50,000 cpm per
well ; Amersham International, Amersham, United Kingdom), which had been diluted in
citrate/phosphate buffer of the appropriate pH . The wells were washed at the same pH .
Parallel incubations were also performed in which the plates were washed at the various
pHs and the immobilized antibody developed with radio-iodinated monoclonal anti-A,
antibody Ls136 (13) in PBS/1% BSA . This confirmed that the pH dependence observed
in the protein A binding assays was indeed a result of the pH dependence of anti-
body/protein A interactions rather than artefact due to washing the chimeric antibody
off the microtiter plate .
C1q Binding and Hemolysis Assays.
￿
Human Clq that had been radioiodinated by the
lactoperoxidase method was a gift from Dr . N . HughesJones and B . Gorick (MRC Centre,
Cambridge, United Kingdom). Human erythrocytes were coupled with NIP-kephalin (gift
ofDr . U . Weltzien, Max Planck Institute For Immunology, Freiburg, Federal Republic
of Germany) as previously described (16), and, if required, were labeled with sodium
[5'Cr]chromate (Amersham International) as previously described (17) . For C 1 q binding
assays, washed NIP-red cells (20 t1 at 109 cells/ml) in PBS/1% BSA were coated with
saturating amounts of antibody (10 tL1 at 200 ug/ml) and then supplemented with
['251]Clq (10 Al at 10-60,ug/ml) . After rotation at 37 °C for 1 h, samples were centrifuged
in microfuge tubes through 150 Al of oil of density 1 .028 (made by mixing four parts di-
n-butyl phthalate with one part dinonyl phthalate) . The cell pellets were separated by
clipping off the bottom of the tube and the radioactivity in the bound and free fraction
was determined . Controls were performed without added antibody; nonspecific binding
was always <1 % .
For hemolytic complement assays, NIP-human red cells were labeled with 15'Cr ]-
chromate, washed, and 50 ul of cells (109/ml) were mixed in microtiter wells with 50 tul
of appropriate dilutions of the chimeric antibodies . After 10 min at room temperature,
100 Al of diluted human complement was added to give a final concentration of 20% .
After a 30-min incubation at 37°C, the cells and supernatant were separated by centri-
fugation (100 g, 2 min) . Samples incubated with no antibody were used to calculate the
spontaneous "Cr release . The percentage specific "Cr release is calculated as : Percent
release = 100 X [(Test release - spontaneous release)]/[(Total radioactivity) - (sponta-
neous release)] .
Antibody-dependent Cell-mediated Cytotoxicity. This was performed essentially as de-
scribed (18) but with modifications. Cells (2 X 106) of the human T cell line HPB-ALL
were labeled in 100,ul of medium with 50 tiCi of sodium [5'Cr]chromate for 30 min at
37 °C, and 2 Al of NIP-kephalin (100 ug/ml) was then added and the incubation was
continued for another 15 min . These target cells were then washed with Hepes-buffered
Iscove's modified DME containing 1% BSA . The effector cells were obtained from healthy
donors by venipuncture and, after defibrination with glass beads, mononuclear cells were
isolated by centrifugation on Ficoll-Hypaque (19) and cultured overnight in Iscove's
MDM/5% FCS . Antibody-dependent cell-mediated cytotoxicity (ADCC) was measured by
mixing labeled target cells (50 Al at 4 X 105/ml) with dilutions (100 Al) of the chimeric
antibodies and then supplementing with the effector cells (50 11 at 1 .2 X 10'/ml) . The
cells were pelleted (200 g, 10 min) and incubated at 37'C for 4 h . The radioactivity in
the supernatant was then measured. Assays were performed in triplicate and controls1354
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pSV - VNP
￿
FIGURE 1.
￿
Structure of plasmids. (A) The
pSV-VNP vector. The mouse IgH enhancer (E)
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a
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C 1 to the Bgl II site 3' ofC.3 . Plasmid pSV-
tx 2
= Nor-
￿
VNpHe hasbeen described previously (3).
performed without effector cells (no lysis was then observed) . The specific 5'Cr release
was calculated as described above .
Results
Cell Lines Expressing Human Chimeric Antibodies .
￿
The basic plasmid that was
used for the construction of the chimeric heavy chain genes (pSV-VNP ) is depicted
in Fig . 1 . The plasmid contains the V gene of a mouse anti-NP antibody .
Upstream of the V,, promoter is the mouse IgH enhancer element ; downstream
ofVH isa unique BamHI restriction site . Differenthuman C,, genes were inserted
either into this Bam HI site or into derivatives of pSV-VNP in which the Bam HI
site was converted to a Hind III or Xba I site by insertion of linkers . The exact
C,, fragments inserted are described in Fig . 1 . In the case of 73, two constructs
were assembled with different y3 genes that originated from different sources,
having been cloned from different individuals.
The gpt marker present in plasmid pSV-VNP allows stably transfected cells to
be selected by virtue of their resistance to the drug mycophenolic acid . The
plasmids were introduced into the mouse plasmacytoma J558L as described in
Materialsand Methods . This plasmacytoma secretes a X, light chain but expresses
no heavy chain of its own . The VA of the endogenous light chain complements
the VNP of the transfected heavy chain to yield an NP-specific antibody ; such
antibodies display a slightly greater affinity for the iodinated derivative, NIP,
than forNP itself.
Antibodies were purified to homogeneity from the culture medium of clonedBROGGEMANN ET AL.
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FIGURE 2 .
￿
Analysis of chimeric antibodies by SDS-PAGE . (A) Antibodies from cells biosyn-
thetically labeled in the presence or absence of tunicamycin (Tm) were analyzed on 10% SDS-
PAGE gels after reduction . (B) Antibodies purified from culture supernatants were analyzed
without reduction on a 7% SDS-PAGE gel . The positions of molecularmass (kD) markers are
indicated .
transfectants ; yields were typically in the range 2 to 10 mg/liter although
sometimes up to 30 mg/liter was achieved .
Analysis ofAntibodies on SDS/PAGE.
￿
To characterize the chimeric antibodies,
purified samples were reduced and analyzed by SDS-PAGE . The mobilities of
the heavy chains were much as predicted on the basis of their DNA sequences
except for u, e, and a2 . We have previously shown (3) that the chimeric e heavy
chains become heavily glycosylated . We therefore resorted to biosynthetic label-
ing to compare the antibody normally secreted by the transfectants with that
made in the presence of the glycosylation inhibitor tunicamycin . The results
(Fig . 2A) demonstrate the IgM, IgE, and IgA2 secreted by the J558L transfec-
tants are indeed heavily glycosylated on their heavy chains . A much smaller
amount ofglycosylation is apparent on the 7 heavy chains . The sizes of the heavy
chains of the unglycosylated antibodies are exactly as predicted from the DNA
sequences (the y3 heavy chains standing out from the other 7 chains because of
the long hinge) .
To examine whether the secreted antibodies were correctly assembled, unre-
duced samples were analyzed on 7% SDS-PAGE gels (Fig . 2B). The IgGs and
IgE exhibit mobilities consistent with their having the expected H2L2 structures
whereas the IgM is clearly of very large molecular weight and, as expected for
the pentameric form, scarcely enters the gel . IgA2 gives the most complex
pattern and appears to contain H, HL,H2L2 , and (H2L2)2 forms ; this may reflect
the secretion of some noncovalently linked molecules .
Serological Characterization .
￿
For potential therapeutic applications, it is clearly
important to establish whether chimeric human antibodies secreted by a mouse
plasmacytoma are indeed homologous to human mAbs . While the analysis on
SDS-PAGE indicated that the chimeric antibodies resembled their human coun-
terparts as regards the molecular weights of both the native and the unglycosy-
lated heavy chains, we decided to extend this characterization to include a wide1356
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HP6031 non-19G2
A55 non-G3m(g)
F10F non-G3m(g)
JD79 non-G3m(g)
HP6080 G3n(O)
anon-19G3
FIGURE 3 .
￿
Molecular localization of epitopes recognized by mAbs to human IgG . For the
origin and specificity of these antibodies see references 24 and 25 . The anti-IgA antibodies
are described in reference26 .
range of serological markers . The chimeric antibodies were therefore typed
using 37 different monoclonal anti-human antibodies (Fig . 3) . On the basis of
this typing (Table I), it will be seen that the two IgG3s are allotypically distinct .
The y3 gene of the XEZZy3 clone (23) yields an IgG3 of the nG3m(g) iso-
allotype ; in other words, it is not of the G3m(g) allotype . Indeed, the DNA
library from which the XEZZ-y3 clone was isolated was made from a Tunisian
individual known to be homozygous for the G3m(b) allotype (23) . However, the
y3 gene from the cosIgI clone (22) yields an IgG.G3m(g) antibody . The chimeric
IgA2 types as nA2m(2), a result that is predicted from the sequence of the a2
gene used here which shows it to be of the A2m(1) allotype (27) . Thus, all the
chimeric antibodies type exactly as expected and the chimeric antibodies are not
therefore serologically distinguished in these assays from authentic human anti-
bodies as regards the CH region determinants .
Binding to Protein A.
￿
The chimeric antibodies were further tested in their
binding of radio-iodinated Staphylococcal protein A over a pH range from 3 to
10 . The results (Fig . 4) indicate that the chimeric IgG1, IgG2, and IgG4 bind
well to protein A and show a very similar pH dependence, binding occurring
down to pH 4.5 . This similarity of pH dependence could be due to titration of
one of the conserved residues in the antibody CH2/CH3 domain binding site for
protein A (see review in reference 9) or could be due to titration ofone of the
protein A side chains themselves . No proteinA binding was detected with IgM,
IgE, IgA2, or either of the IgG3s.
Binding ofHuman CIq .
￿
The binding of C1q to the chimeric antibodies was
Cy3 I
INTER
DOMAIN I Cy2 I HINGE Cyl
8a4 We10 JD312 SG4-IgG3 TN15
J10d QC1l G7c HP6044
x3.8 non-IgG4 WC2 JL512 IgG1 HP6046
1al non-IgG4 QF1" NL16 IgG1 TN10 - non-IgG1
3910 non-IgG4 VC9' GON1 IgG2 TH14 Glm(f)
49/2C3 non-IgG4 F7c* GON2 IgG2 HP6014 IgG2
RJ4 IgG4 GB7B IgG4* The y3 C region derives from clone coslgl (22) .
$ The y3 C region derives from phage XEZZy3 (23) .
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TABLE I
Serological Typing of Chimeric Antibodies
Ig6l IgG2 IgG4
- i
3 4 5 6 7 8 9 10 3 4 5 6 7 8 9 10 3 4 5 6 7 8 9 10
pH
￿
pH
￿
pH
FIGURE 4 .
￿
Binding of protein A to chimeric antibodies. The amount of radio-iodinated
protein A bound to immobilized antibodies is plotted as a function ofpH . No binding was
detected to the IgM, IgE, IgA2, or either of the IgG3s over the entirepH range tested .
assayed using various concentrations of radiolabeled C 1qand hapten-derivatized
red cells that were coated with amounts of antibody that were shown to be
saturating . The results (Fig . 5, left) show that Clq binding is detected with the
IgM, IgGI, and both IgG3 antibodies but not with IgG2, IgG4, or IgE. The
binding to IgM is weaker than to IgG 1 and IgG3 and, ofthesetwo IgG subclasses,
the IgG3s bound more Clq than did the IgGI .
Complement-mediated Hemolysis .
￿
Antibodies were tested over a wide concen-
tration range for their ability to lyse hapten-coupled human red cells in the
presence of human complement . The results (Fig . 5, right) show that IgG2,
IgG4, and IgE did not mediate hemolysis, whereas IgM, IgG1, and both IgG3s
were effective . Indeed, it is notable that the IgG 1 was considerably more effective
in this hemolytic assay than the IgG3s.We have previously demonstrated (17) that
Specificity
Number
used IgGI IgG2
Chimeric antibody
IgG3* IgG3$ IgG4 IgA2 IgM
IgG 7 + + + + + ND ND
IgGI 1 + - - - - ND ND
Glm(f) 1 - - - - - ND ND
IgG2 1 - + - - - ND ND
IgG2,3,4 I - + + + + ND ND
IgG1,2,4 5 + + - - + ND ND
IgG3 1 - - + + - ND ND
G3m(u) 1 - - + + - ND ND
nG3m(g) 4 + + - + + ND ND
IgG4 1 - - - - + ND ND
IgG1,2,3 2 + + + + - ND ND
IgA 1 ND ND ND ND ND + ND
IgAI 3 ND ND ND ND ND - ND
IgA2 I ND ND ND ND ND + ND
nA2m(2) 1 ND ND ND ND ND + ND
IgM 6 ND ND ND ND ND ND +w
Q
V
v e
0 m
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IgG.G3m(g)
5 I-5 1.4 1-3 °f.2
￿
-1
10 10 10 10 10 10
Antibody Concentration (mg/ml)
" IgG1
AL IgG.G3m(b)
0IgM
I.G2
+I:A
" IgG4
IgE
Input C1q Concentration (NWml)
￿
Antibody
￿
Concentration
￿
((tg/ml)
FIGURE 5. Binding of Clq and complement-dependent hemolysis by chimeric antibodies .
(Right) Binding of various concentrations of radiolabeled Clq to NIP-human red cells that
have been coated with saturating amounts of chimeric antibody . (Left) Lysis of [51Cr]NIP-
human red cells by various concentrations of chimeric antibody in the presence of human
complement . The allotypes of the two IgG3 antibodies [IgG.G3m(b) and IgG.G3m(g)] are
indicated .
FIGURE 6. ADCC by chimeric antibodies . The
V IgG.Wrn(g) lysis of [51 Cr]NIP-conjugated human target cells
(HPB-ALLT cell line)by human PBMC was meas-
ured as a function of the concentration of anti-NP
chimeric antibody .
the efficacy of anti-NP antibodies in this hemolytic assay is critically dependent
on their affinity forthe hapten . However, this cannot explainthe results obtained
here . Binding-inhibition assays (not shown) indicate that the IgG 1 and IgG3
antibodies have indistinguishable affinities for NIP-caproate . Furthermore, the
IgGI and IgG3 samples gave very similar titers in hemagglutination assays using
hapten-derivatized red cells . Thus, although IgG3 is the best subclass as regards
C1q binding it is considerably less potent than IgG 1 in hemolytic assays . Inter-
estingly, a similar but less marked reversal of hemolytic efficiency as compared
with Clq binding is observed with the two IgG3 allotypes . Whereas the
IgG.G3m(g)binds Clqslightly better, the IgG.G3m(b) is somewhat more effective
in hemolysis .
Antibody-dependent Cell-mediated Cytotoxicity .
￿
The efficacy of the antibodies in
mediatingADCC was tested using a hapten-derivatized human T cell line (HPB-
ALL) as target and mononuclear cells from human volunteers as effector cells .
It was found (Fig . 6) that only IgGI and IgG3 were effective in mediating ADCC
with the IgG 1 showing greater potency than either of the IgG3s .BROGGEMANN ET AL .
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Discussion
The cell lines established during the course of this work provide a source of
chimeric antibodies that can be easily purified to homogeneity in a one-step
purification on hapten sorbents . To confirm that these chimeric human antibod-
ies made in mouse plasmacytoma cells exhibit the features expected of antibodies
possessing human C regions, we have characterized the antibodies as regards
their serological properties, the mobilities in SDS-PAGE of both the native and
the unglycosylated forms as well as their binding to protein A. In all these
respects, the chimeric antibodies behave exactly as expected from theirauthentic
human counterparts .
The known antigen specificity of these chimeric antibodies has allowed us to
assay their efficacy in complement-mediated lysis and in ADCC . This has given
rise to some novel and unexpected findings . The hierarchy of the binding of the
aggregated chimeric IgG subclasses to human Clq described here agrees well
with the previous results on the hierarchy in C 1q binding of monomer IgG
myeloma subclasses (28) ; however, aggregated IgGwill bind with a higher avidity
than monomeric IgG. Nevertheless, when we measured the efficacy of the
antibodies in complement-mediated hemolysis, a very different result was ob-
tained . It is evident that the IgGI is very much more effective than the IgG3 in
this assay. At present it is not clear why there is this lack of correlation between
Clq binding and hemolytic efficacy ; it will clearly be of interest to compare the
IgG1 and IgG3 chimeric antibodies in intermediate stages of the pathway such
as C1 activation andC4 and C3 binding . It will also be of interest to determine
how the comparative hemolytic efficacy of IgGI and IgG3 depends upon the
density and nature of the antigen on the target cell .
The results presented here also indicate that the IgGI and IgG3 are the only
antibodies that are really effective in ADCC . The greater effectiveness of IgGI
as compared with IgG3 is a novel and interesting finding . The relative inactivity
of the IgG2 and IgG4 antibodies was, however, predictable . Although the exact
nature of the effector cell responsible for mediatingADCC has not been unam-
biguously identified, the Fc receptors found on the possible effector cell types
(lymphocytes and monocytes) bind IgGI and IgG3 much better than IgG2 and
IgG4 (reviewed in reference 9) .
Finally, it is worth noting that the results obtained in this work suggest that
for many therapeutic purposes an IgGI antibody might be greatly preferred to
the other IgG subclasses as it appears to be considerably more effective in
mediating both complement-dependent lysis and ADCC .
Summary
Cell lines have been established that secrete a matched set of human chimeric
IgM, IgG l, IgG2, IgG3, IgG4, IgE, and IgA2 antibodies that aredirected against
the hapten 4-hydroxy-3-nitrophenacetyl . These chimeric antibodies secreted
from mouse plasmacytoma cells behave exactly like their authentic human
counterparts in SDS-PAGE analysis, binding to protein Aand in a wide range of
serological assays. The antibodies have been compared in their ability to bind
human Clq as well as in their efficacy in mediating lysis ofhuman erythrocytes
in the presence of human complement . A major conclusion to emerge is that1360
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whereas IgG3 bound C 1q better than did IgG l , the chimeric 1gG1 was much
more effective than all the other IgG subclasses in complement-dependent
hemolysis . The IgG1 antibody was also the most effective in mediating antibody-
dependent cell-mediated cytotoxicity using both human effector and human
target cells. These results suggest that IgGI might be the favoured IgG subclass
for therapeutic applications .
We are indebted to Catherine Teale and Mark Frewin for invaluable technical assistance
and to B . Gorick, T. Honjo, N. HughesJones, M.-P . Lefranc, C. P . Milstein, T. H.
Rabbitts, and U . Weltzien for gifts ofDNA clones or reagents .
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